# Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial

- **DOI:** [10.1016/s0140-6736(21)02225-x](https://doi.org/10.1016/s0140-6736(21)02225-x)
- **Rating:** Strong (4.0 out of 5)
- **Verdict:** Garadacimab establishes placebo-controlled proof of concept for FXIIa-targeted HAE prophylaxis, but the small, 12-week trial leaves definitive benefit–risk assessment unresolved.
- **Framework version:** v5.10
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-11-02
- **Evaluation page:** https://www.nabu.science/paper/10.1016%2Fs0140-6736(21)02225-x

## Key claims

1. Compared with placebo, the rate of attacks was significantly reduced with garadacimab at 200 mg (reduced by 100% [95% CI 98–101]; p=0·0002) and 600 mg (reduced by 93% [54–110]; p=0·0003).
   - Support: Supported
   - Type: Primary finding
   - Basis: large randomized effects over 12 weeks, with small treatment arms limiting precision
   - Location: Summary, Findings
2. Across all treatment groups, no serious adverse events or adverse events of special interest (ie, anaphylaxis, thromboembolic events, or bleeding) were observed, showing that subcutaneous treatment with garadacimab was well tolerated for up to 12 weeks.
   - Support: Supported
   - Type: Secondary
   - Basis: systematic short-term observation with too few treated patients to exclude uncommon harms
   - Location: Discussion, paragraph beginning ‘Across all treatment groups’
3. All eight patients (100%) treated with 200 mg garadacimab had a reduction in the number of monthly attacks of at least 90% and seven (88%) were attack free (figure 3).
   - Support: Supported
   - Type: Secondary
   - Basis: directly reported response counts from an eight-person treatment arm
   - Location: Results, paragraph beginning ‘During the 12-week subcutaneous period’
4. Therefore, in our study, maximal efficacy was at 200 mg every 4 weeks, and an increase to 600 mg did not appear to result in an increase in efficacy.
   - Support: Tentative
   - Type: Secondary
   - Basis: no powered active-dose comparison established maximal efficacy at 200 mg
   - Location: Discussion, paragraph beginning ‘Although we observed improved efficacy and safety’

## Strengths

- **Controlled evidence validates a distinct target** The trial demonstrates large placebo-controlled reductions in attacks with FXIIa inhibition, extending the clinical evidence beyond existing C1-INH and kallikrein-directed approaches.
  - Dimension: contribution
  - Location: Research in context; Results, primary efficacy analysis
- **Concealed allocation and complete efficacy accounting** Interactive-response allocation, masked participants and investigators, volume-normalised syringes, and complete ITT attack-rate data protect the primary comparison from avoidable execution bias.
  - Dimension: methodological rigour
  - Location: Methods, Randomisation and masking; Statistical analysis
- **Systematic assessment of short-term treatment harms** Adverse events were defined, MedDRA-coded, and assessed alongside special-interest events, laboratory findings, and anti-drug antibodies. Table 2 reports events and patient denominators by treatment group.
  - Dimension: methodological rigour
  - Location: Methods, Procedures and Outcomes; Table 2

## Limitations

- **Small arms and short observation constrain inference** Only seven to nine participants were assigned to each arm, with 12 weeks of blinded subcutaneous treatment. This limits effect-size precision and assessment of durable benefit or uncommon harms.
  - Dimension: methodological rigour
  - Location: Results, randomized population; Discussion, limitations paragraph
- **Preferred dose lacks direct comparative confirmation** The claim of maximal efficacy at 200 mg rests on numerical response differences and post-hoc modelling rather than a powered active-dose comparison. The observed non-monotonic response leaves dose selection unresolved.
  - Dimension: reporting
  - Location: Discussion, dose-response and optimal-benefit–risk paragraphs
- **Comparative positioning remains largely feature based** The discussion emphasises mechanism and dosing convenience without quantitatively comparing benefit–risk against licensed prophylactic alternatives. Those features establish differentiation, not comparative superiority.
  - Dimension: positioning
  - Location: Research in context; Discussion, prophylactic alternatives paragraph

## Reliability checks

Caveats (4 of 4 checks).

- **Results check:** Noted. One reported value does not reconcile, but the key claims do not rest on it.
  - [Garadacimab] significantly reduced the monthly attack rate at 200 mg (100% [95% CI 98–101]) and 600 mg (93% [54–110]) versus placebo: "reduced by 93% [54–110]; p=0·0003" (Summary, Findings). The reported upper bounds of 101% and 110% exceed the feasible 100% reduction boundary, although an unconstrained interval can extend outside a parameter's feasible range without invalidating the efficacy test. → Conclusion holds
- **Reporting and transparency:** Noted. The Results report an incorrect male percentage, while the participant count and arm-level counts agree. Ethics, consent, registration, sponsor involvement, conflicts, and conditional data access are declared.
  - Conflict of interest: declared · Ethics approval: declared · Preregistration: declared · Data availability: declared · Code availability: not stated
- **Reference integrity:** Clean
  - 25 references in manuscript
  - 25 of 25 checkable references found in an index
  - 2 references confirmed by manual review
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-11-02
